AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
While it had managed to rebound from that setback, AbbVie's shares fell off a cliff late last year when one of its exciting ...
Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
a Represents net earnings (loss) attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset ...
Also Read: AbbVie’s Early Parkinson’s Candidate Hits Primary Goal In Pivotal Late-Stage Study Despite this, the company sees potential in exploring emraclidine as an adjunctive treatment ...
So is the stock worth buying today? AbbVie had a recent setback in November when it announced poor phase 2 study results for emraclidine. The once-promising drug was a potential blockbuster for ...
after-tax impairment charge related to its investigational antipsychotic drug emraclidine that hasn't been included in management's guidance. AbbVie is one of the better pharmaceutical stocks on ...